• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate.

作者信息

Barreto Jason N, Kashani Kianoush B, Mara Kristin C, Rule Andrew D, Lieske John C, Giesen Callen D, Thompson Carrie A, Leung Nelson, Witzig Thomas E, Barreto Erin F

机构信息

Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.

Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Kidney Int Rep. 2022 Mar 26;7(7):1690-1693. doi: 10.1016/j.ekir.2022.03.013. eCollection 2022 Jul.

DOI:10.1016/j.ekir.2022.03.013
PMID:35812294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9263243/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf91/9263243/6317c13ff8ab/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf91/9263243/6317c13ff8ab/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf91/9263243/6317c13ff8ab/gr1.jpg

相似文献

1
A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate.对接受大剂量甲氨蝶呤治疗的淋巴瘤患者新型肾脏生物标志物的前瞻性评估。
Kidney Int Rep. 2022 Mar 26;7(7):1690-1693. doi: 10.1016/j.ekir.2022.03.013. eCollection 2022 Jul.
2
Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury.尿组织金属蛋白酶抑制剂-2 和胰岛素样生长因子结合蛋白 7 作为已确诊急性肾损伤患者的生物标志物。
Korean J Intern Med. 2020 May;35(3):662-671. doi: 10.3904/kjim.2018.266. Epub 2019 Dec 23.
3
Urinary biomarkers of cell cycle arrest are delayed predictors of acute kidney injury after pediatric cardiopulmonary bypass.细胞周期阻滞的尿生物标志物是小儿体外循环后急性肾损伤的延迟预测因子。
Pediatr Nephrol. 2017 Dec;32(12):2351-2360. doi: 10.1007/s00467-017-3748-7. Epub 2017 Jul 28.
4
Mechanisms Underlying Increased TIMP2 and IGFBP7 Urinary Excretion in Experimental AKI.实验性 AKI 中 TIMP2 和 IGFBP7 尿排泄增加的机制。
J Am Soc Nephrol. 2018 Aug;29(8):2157-2167. doi: 10.1681/ASN.2018030265. Epub 2018 Jul 6.
5
Elevated Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor Binding Protein-7 Predict Drug-Induced Acute Kidney Injury.尿组织金属蛋白酶抑制剂-2 和胰岛素样生长因子结合蛋白-7 升高可预测药物性急性肾损伤。
Curr Drug Metab. 2022;23(3):223-232. doi: 10.2174/1389200223666220425111931.
6
Early recognition of cardiac surgery-associated acute kidney injury: lack of added value of TIMP2 IGFBP7 over short-term changes in creatinine (an observational pilot study).心脏手术相关急性肾损伤的早期识别：TIMP2 IGFBP7 对肌酐短期变化无额外价值（观察性初步研究）。
BMC Anesthesiol. 2021 Oct 13;21(1):244. doi: 10.1186/s12871-021-01387-6.
7
Urine Biomarkers for the Assessment of Acute Kidney Injury in Neonates with Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia.接受治疗性低体温的患有缺氧缺血性脑病的新生儿急性肾损伤的尿液生物标志物评估。
J Pediatr. 2022 Feb;241:133-140.e3. doi: 10.1016/j.jpeds.2021.08.090. Epub 2021 Sep 20.
8
Tissue inhibitor metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) best predicts the development of acute kidney injury.组织金属蛋白酶抑制剂2（TIMP-2）和胰岛素样生长因子结合蛋白7（IGFBP7）最能预测急性肾损伤的发生。
Heliyon. 2021 Sep 6;7(9):e07960. doi: 10.1016/j.heliyon.2021.e07960. eCollection 2021 Sep.
9
Kinetic eGFR and Novel AKI Biomarkers to Predict Renal Recovery.预测肾脏恢复的动态估算肾小球滤过率和新型急性肾损伤生物标志物
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1900-10. doi: 10.2215/CJN.12651214. Epub 2015 Sep 4.
10
Will urinary biomarkers provide a breakthrough in diagnosing cardiac surgery-associated AKI? - A systematic review.尿生物标志物能否为诊断心脏手术相关 AKI 带来突破？——系统评价。
Biomarkers. 2020 Jul;25(5):375-383. doi: 10.1080/1354750X.2020.1777199. Epub 2020 Jun 19.

引用本文的文献

1
Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches.化疗所致急性肾损伤：流行病学、病理生理学及治疗方法
Front Nephrol. 2024 Aug 9;4:1436896. doi: 10.3389/fneph.2024.1436896. eCollection 2024.

本文引用的文献

1
Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.淋巴瘤患者接受大剂量甲氨蝶呤序贯治疗时，早期经验性大剂量亚叶酸钙解救。
Support Care Cancer. 2021 Sep;29(9):5293-5301. doi: 10.1007/s00520-021-06106-y. Epub 2021 Mar 4.
2
Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement.急性疾病质量倡议共识会议关于急性肾损伤生物标志物的建议：共识声明。
JAMA Netw Open. 2020 Oct 1;3(10):e2019209. doi: 10.1001/jamanetworkopen.2020.19209.
3
Creatinine: From physiology to clinical application.
肌酸酐：从生理学到临床应用。
Eur J Intern Med. 2020 Feb;72:9-14. doi: 10.1016/j.ejim.2019.10.025. Epub 2019 Nov 8.
4
Assessment of renal function during high-dose methotrexate treatment in children with acute lymphoblastic leukemia.急性淋巴细胞白血病患儿大剂量甲氨蝶呤治疗期间的肾功能评估
Pediatr Blood Cancer. 2014 Dec;61(12):2199-202. doi: 10.1002/pbc.25137. Epub 2014 Aug 31.
5
Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication.采用临床裁决验证细胞周期停滞生物标志物在急性肾损伤中的应用。
Am J Respir Crit Care Med. 2014 Apr 15;189(8):932-9. doi: 10.1164/rccm.201401-0077OC.
6
High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.淋巴瘤患者中与甲氨蝶呤相关的肾毒性发生率高：一项回顾性分析
Leuk Lymphoma. 2014 Jun;55(6):1345-9. doi: 10.3109/10428194.2013.840780. Epub 2013 Nov 1.
7
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.人类急性肾损伤中细胞周期阻滞生物标志物的发现与验证
Crit Care. 2013 Feb 6;17(1):R25. doi: 10.1186/cc12503.
8
Acute renal problems in the critically ill cancer patient.危重症癌症患者的急性肾脏问题。
Curr Opin Crit Care. 2008 Dec;14(6):635-46. doi: 10.1097/MCC.0b013e32830ef70b.
9
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.甲氨蝶呤联合延迟放疗治疗原发性中枢神经系统淋巴瘤：NABTT 96 - 07报告
J Clin Oncol. 2003 Mar 15;21(6):1044-9. doi: 10.1200/JCO.2003.03.036.